ATRC

AtriCure's Financial Performance: AtriCure (ATRC) reported $134.27 million in revenue for Q3 2025, a 15.8% increase year-over-year, with an EPS of -$0.01, significantly improving from -$0.17 a year ago.

Market Expectations and Surprises: The revenue exceeded the Zacks Consensus Estimate by 2.09%, while the EPS surprise was +90.91%, indicating stronger-than-expected performance.

Stock Performance: AtriCure's shares have declined by 4.02% over the past month, contrasting with a 0.95% increase in the Zacks S&P 500 composite, and the stock holds a Zacks Rank #2 (Buy).

Investment Insights: Zacks Investment Research highlights a satellite-based communications firm as a top stock pick, projecting significant revenue growth in the trillion-dollar space industry, alongside other high-potential stocks.

Put Contract Overview: The $35.00 put contract has a bid of 10 cents, allowing investors to buy ATRC shares at a cost basis of $34.90, which is a 4% discount from the current price of $36.41. There is a 62% chance the contract may expire worthless, offering a potential 0.29% return on cash commitment.

Call Contract Overview: The $40.00 call contract has a bid of 5 cents, enabling investors to sell ATRC shares at that price, which represents a 10% premium over the current stock price. If the contract expires worthless, investors could retain their shares and earn a 0.14% additional return.

Volatility Insights: The implied volatility for the put contract is 61%, while the call contract has an implied volatility of 68%. The actual trailing twelve-month volatility is calculated at 49%.

YieldBoost Concept: The article discusses the concept of YieldBoost, which refers to the additional returns investors can earn from options contracts, highlighting the potential returns from both the put and call contracts discussed.